- Independent mouse study conducted at Case Western Reserve University School of Medicine,
published in OncoImmunology, builds on body of evidence
demonstrating cryoablation can activate the body's natural immune
response by enhancing CD8+ T cells, which are an important arm of
immune response
- Data support previous studies and suggest ProSense®
may produce anti-cancer benefits in humans beyond tumor destruction
during cryoablation procedure
CAESAREA, Israel, Jan. 3, 2024
/PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM), developer of
the ProSense® System, a minimally-invasive cryoablation technology
that destroys tumors by freezing as an alternative to surgical
tumor removal, today announced the publication of a study titled
"Piezo1 facilitates optimal T cell activation during tumor
challenge" in the highly influential peer-reviewed journal
OncoImmunology. The study, conducted at Case Western Reserve University School of Medicine
in Cleveland, Ohio, by
Muta Abiff et al, utilized ProSense®
for cryoablation procedures in a mouse model to explore the role of
the Piezo1 protein in regulating T-cell tumor immune-mediated
rejection of soft tissue tumors.
The Piezo1 study involved performing cryoablation with ProSense®
on tumor volumes of approximately 100 mm3 (diameter ~6 mm) using a
mouse model. The cryoprobe was placed percutaneously directly on
the tumor mass. The data demonstrates that cryoablation induces
immune rejection by enhancing CD8+ T cell activation, a process
dependent on T cell expression of Piezo1. Increased activation and
responsiveness, potentially leading to a more robust immune
response against abnormal cells, was detected up to 2 weeks after
cryoablation, displayed as an increase in CD25 and interferon gamma
(IFNγ) expression on CD8+ T cells.
In the field of cryoimmunology, cryoablation is known to induce
potent T cell-dependent tumor rejection. Prior independent research
using ProSense® to explore cryoablation's antitumor activity
includes a study titled "Functional tumor cell-intrinsic STING, not
host STING, drives local and systemic antitumor immunity and
therapy efficacy following cryoablation" by Alshebremi et al
published in August 2023 in the
Journal of ImmunoTherapy of Cancer. The study
demonstrated the unequivocal role of an ongoing and functional
STING pathway as a major driver of local control and the systemic
abscopal effects on advanced tumors following cryoablation.
"Preclinical data from both of these independent studies
demonstrate the unique mechanism of action through which ProSense®
induces the activation of immune cells which are critical to
increasing the potential therapeutic benefits of cryoablation
against solid tumors. These benefits extend beyond the destruction
of the tumor through our minimally invasive procedure, by
activating the immune system for weeks following the procedure,"
stated IceCure's Chief Executive Officer, Eyal Shamir. "These studies pave the way for
analysis of immune response in the growing number of ProSense®
cryoablation investigator-initiated trials in humans. As always, we
are very grateful to the doctors conducting these independent
studies that explore and confirm ProSense®'s mechanism of action
and its benefits for patients."
About ProSense®
The ProSense® Cyroablation System provides a minimally
invasive treatment option to destroy tumors by freezing them. The
system uniquely harnesses the power of liquid nitrogen to create
large lethal zones for maximum efficacy in tumor destruction in
benign and cancerous lesions, including breast, kidney, lung, and
liver.
ProSense® enhances patient and provider value by
accelerating recovery, reducing pain, surgical risks, and
complications. With its easy, transportable design and liquid
nitrogen utilization, ProSense® opens that door to fast and
convenient office-based procedure for breast tumors.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®,
an advanced liquid-nitrogen-based cryoablation therapy for the
treatment of tumors (benign and cancerous) by freezing, with the
primary focus areas being breast, kidney, bone and lung cancer. Its
minimally invasive technology is a safe and effective alternative
to hospital surgical tumor removal that is easily performed in a
relatively short procedure. The system is marketed and sold
worldwide for the indications cleared and approved to date
including in the U.S., Europe, and
China.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal and
Israeli securities laws. Words such as "expects," "anticipates,"
"intends," "plans," "believes," "seeks," "estimates" and similar
expressions or variations of such words are intended to identify
forward-looking statements. For example, IceCure is using forward
looking statement in this press release when it discusses: the
expected plan and progress towards completion of the follow-up on
the ICE3 clinical study in February
2024; evaluating all strategies to efficiently and
effectively address the FDA's comments; and the expected 5-year
results passed on the interim analysis of the ICE3 trial. Historic
results of scientific research and clinical and preclinical trials
do not guarantee that the conclusions of future research or trials
will suggest identical or even similar conclusions. Because such
statements deal with future events and are based on IceCure's
current expectations, they are subject to various risks and
uncertainties and actual results, performance, or achievements of
IceCure could differ materially from those described in or implied
by the statements in this press release. The forward-looking
statements contained or implied in this press release are subject
to other risks and uncertainties, many of which are beyond the
control of the Company, including those set forth in the Risk
Factors section of the Company's Annual Report on Form 20-F for the
year ended December 31, 2022 filed
with the SEC on March 29, 2023, and
other documents filed with or furnished to the SEC which are
available on the SEC's website, www.sec.gov. The Company undertakes
no obligation to update these statements for revisions or changes
after the date of this release, except as required by law.
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo -
https://mma.prnewswire.com/media/1941429/IceCure_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/new-study-reports-icecures-prosense-boosts-immune-response-against-cancer-enhances-cd8-t-cell-response-302025257.html
SOURCE IceCure Medical